Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3B, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety of Pegcetacoplan in a Prefilled Syringe in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT07214740 is registered in ClinicalTrials.gov with Apellis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07214740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07214740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3B, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety of Pegcetacoplan in a Prefilled Syringe in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Lead sponsor
Apellis Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 24, 2025
Completion date
December 12, 2025
Enrollment
44 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy secondary to age-related macular degeneration